Effect of Previous or Simultaneous Immunization with Canarypox Expressing Cytomegalovirus (CMV) Glycoprotein B (gB) on Response to Subunit gB Vaccine plus MF59 in Healthy CMV-Seronegative Adults

• Published in: The Journal of infectious diseases Vol. 185; no. 5; pp. 686 - 690
• Main Authors: Bernstein, David I., Schleiss, Mark R., Berencsi, Klara, Gonczol, Eva, Dickey, Michelle, Khoury, Phil, Cadoz, Michel, Meric, Claude, Zahradnik, John, Duliege, Anne-Marie, Plotkin, Stanley
• Format: Journal Article
• Language: English
• Published: Chicago, IL The University of Chicago Press 01.03.2002; University of Chicago Press
• Subjects: Adjuvants, Immunologic - administration & dosage; Adolescent; Adult; Antibodies; Antibodies, Viral - blood; Bacteriology; Biological and medical sciences; Concise Communication; Cytomegalovirus; Cytomegalovirus infections; Cytomegalovirus Infections - prevention & control; Cytomegalovirus Vaccines - administration & dosage; Cytomegalovirus Vaccines - immunology; Dosage; Enzyme linked immunosorbent assay; Fundamental and applied biological sciences. Psychology; Glycoproteins; Humans; Immunization; Immunization Schedule; Immunization, Secondary; Lymphocyte Activation; Microbiology; Middle Aged; Pain; Placebos; Polysorbates - administration & dosage; Squalene - administration & dosage; Squalene - immunology; Vaccination; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies; Vaccines, Subunit - administration & dosage; Vaccines, Subunit - immunology; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - immunology; Viral Envelope Proteins - genetics; Viral Envelope Proteins - immunology; Viral Envelope Proteins - metabolism; Viral Vaccines - administration & dosage; Viral Vaccines - genetics; Viral Vaccines - immunology; Virology; Cytomegalovirus; Chordopoxvirinae; Immunization; Immune response; Antibody; Toxicity; Herpesviridae; Vaccination; Glycoprotein; Malignant hemopathy; Vaccine; Subunit; Betaherpesvirinae; Virus; Prevention; Avipoxvirus; Immunogenicity; Poxviridae; Lymphoproliferative syndrome; Development
• ISSN: 0022-1899; 1537-6613
• DOI: 10.1086/339003

Development of a vaccine for prevention of congenital cytomegalovirus (CMV) disease is a priority. This study evaluated a “prime-boost” strategy by comparing the safety and immunogenicity of 3 doses of subunit CMV glycoprotein B (gB) vaccine plus MF59 (a squalene-in-water emulsion), 2 doses of a canarypox recombinant vaccine expressing CMVgB (ALVAC-CMVgB) followed by 2 doses of the subunit gB vaccine, 3 doses of both vaccines administered concomitantly, and placebo in 105 healthy, CMV-seronegative adults. Systemic adverse events were rare, but local reactions were common in all groups. After the first subunit vaccination, neutralizing antibody titers in the prime-boost group were comparable to those in subjects receiving 2 subunit vaccinations, indicating a priming effect of ALVAC-CMVgB. However, after the final dose, antibody and cell-mediated immune responses were not significantly different among the groups. All 3 vaccine regimens induced high-titer antibody and lymphoproliferative responses, but no benefit for priming or simultaneous vaccination was detected.